Order Article Reprints

Caviglia GP, Nicolosi A, Abate ML, Carucci P, Rosso C, Rolle E, Armandi A, Aneli S, Olivero A, Risso A, et al. Liver Cancer-Specific Isoform of Serine Protease Inhibitor Kazal for the Detection of Hepatocellular Carcinoma: Results from a Pilot Study in Patients with Dysmetabolic Liver Disease. Current Oncology. 2022; 29(8):5457-5465. https://doi.org/10.3390/curroncol29080431

Caviglia, Gian Paolo, Aurora Nicolosi, Maria Lorena Abate, Patrizia Carucci, Chiara Rosso, Emanuela Rolle, Angelo Armandi, Serena Aneli, Antonella Olivero, Alessandra Risso, and et al. 2022. "Liver Cancer-Specific Isoform of Serine Protease Inhibitor Kazal for the Detection of Hepatocellular Carcinoma: Results from a Pilot Study in Patients with Dysmetabolic Liver Disease" Current Oncology 29, no. 8: 5457-5465. https://doi.org/10.3390/curroncol29080431

Caviglia, G. P., Nicolosi, A., Abate, M. L., Carucci, P., Rosso, C., Rolle, E., Armandi, A., Aneli, S., Olivero, A., Risso, A., Ribaldone, D. G., Fermer, C., Saracco, G. M., Gaia, S., & Bugianesi, E. (2022). Liver Cancer-Specific Isoform of Serine Protease Inhibitor Kazal for the Detection of Hepatocellular Carcinoma: Results from a Pilot Study in Patients with Dysmetabolic Liver Disease. Current Oncology, 29(8), 5457-5465. https://doi.org/10.3390/curroncol29080431